RXRX vs ZYME
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
RXRX presents a classic high-risk, high-reward biotech profile, characterized by a stable Piotroski F-Score of 4/9 and a strong liquidity position (Current Ratio 5.50). While revenue growth is astronomical at 681.70% YoY, the company suffers from extreme operating losses (-328.80% margin) and a bearish insider sentiment. The lack of an Altman Z-Score and Graham Number reflects the pre-profit nature of the business, making it a speculative play on AI-driven drug discovery rather than a value investment.
ZYME exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating a failing financial trajectory. Despite a strong liquidity position (Current Ratio 5.88) and low debt, the company has suffered a catastrophic revenue collapse of -91.90% YoY. There is a stark divergence between the 'Strong Buy' analyst consensus and the bearish insider activity, with executives selling $4.67M in shares. The valuation is speculative, trading at a high Price/Sales multiple of 19.23 despite negative margins and shrinking top-line growth.
Compare Another Pair
Related Comparisons
RXRX vs ZYME: Head-to-Head Comparison
This page compares Recursion Pharmaceuticals, Inc. (RXRX) and Zymeworks Inc. (ZYME) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.